NCT05745233View on ClinicalTrials.gov

Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

NAEnrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Malignant Ascites
Interventions
DRUG

Nivolumab

Intraperitoneal administration of nivolumab Nivolumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.

DRUG

Pembrolizumab

Intraperitoneal administration of pembrolizumab Pembrolizumab 20 mg in normal saline 100ml will be infused intraperitoneally through a temporary catheter in 10 minutes after paracentesis in a weekly interval.

Trial Locations (1)

404

China Medical University Hospital, Taichung

All Listed Sponsors
lead

China Medical University Hospital

OTHER